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Background: The polycystic ovary syndrome (PCOS) is a complex and heterogeneous endocrine condition
characterized by hyperandrogenism, hyperinsulinemia, insulin resistance and chronic anovulation. Regulation and
interaction of a multitude of genes required for follicular development are found to be altered in PCOS. MicroRNAs
(miRNAs) mediate posttranscriptional gene regulation by binding to the 3´ untranslated region of mRNAs to either
inhibit or enhance translation. However, the extent and regulation of miRNA expression in PCOS is poorly
understood and the current study is the first to describe altered expression of miRNAs in PCOS.
Methods: A chronically androgenized [5α-dihydrotestosterone (DHT)-treated] rat model which recapitulates many
of the phenotypes of human PCOS, and miRNA PCR array was used to investigate the expression of 349 miRNAs in
DHT treated rat ovaries. The ovarian expression of several selected miRNAs was also analyzed by in situ localization
experiment.
Results: DHT-treated rats exhibit increased body weight, disrupted estrus cyclicity, decreased insulin sensitivity and
decreased ovarian weight, with the latter phenomenon readily rescued by gonadotropin treatment in vivo. In
general, 24% of the 349 miRNAs investigated were found to be differentially expressed between DHT-treated and
control rats. Most of the differentially expressed miRNAs were found to be predominantly localized in the theca
cells of the follicles. In silico analysis of the potential target genes of dysregulated miRNAs revealed their possible
involvement in various pathways in the regulation of ovarian function.
Conclusion: Our current findings suggest that miRNAs are differentially regulated in hyperandrogenism, a condition
possibly involved in the dysregulation of steroid hormone receptors and intra-ovarian factors, and that miRNAs may
be involved in the etiology of PCOS.
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Polycystic ovary syndrome (PCOS), a multi-factorial
endocrine condition, affects up to 5-10% of women in
reproductive age and accounts for 75% of anovulatory
infertility [1-3]. PCOS is a heterogeneous syndrome with
complex pathologies with follicle growth arrest at the* Correspondence: btsang@ohri.ca
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reproduction in any medium, provided the orsmall antral stage, minimal granulosa cell proliferation,
hyperthecosis and hyperandrogenemia, and chronic
anovulation [1]. It is associated not only with infertility,
but also with increased risk of metabolic disorders, such
as insulin resistance, diabetes, obesity, and cardiovascu-
lar diseases [4]. Both genetic and environmental factors
are known to contribute to the pathogenesis of PCOS;
however, its etiology is unclear.
Differential gene expression is evidenced in human
PCOS ovaries when compared to the normal ones [5].
Genomic studies in PCOS have revealed a variety of al-
tered genes that fall into many functional categories, in-
cluding cell division, apoptosis and regulation of gene
expression and metabolism. While genes involved inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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biosynthesis and luteinizing hormone-responsive gene, are
generally up-regulated in theca cells of PCOS subjects
[6], those associated with Wnt signalling and ovarian
folliculogenesis appear to be down-regulated [7,8]. Al-
though ovarian apoptotic genes are altered in PCOS, the
net effect of these changes is unclear [7]. In addition, sig-
nificant differences in mRNA abundance in oocytes from
PCOS patients have also been reported and cluster analysis
of 374 genes indicated an association with chromosomal
alignment and segregation in mitosis and/or meiosis [9].
Despite ample evidences on gene dysregulation in
PCOS ovary as reported above, precisely how these
genes are transcriptional and post-transcriptional regu-
lated is poorly understood. New advances in post-
transcriptional gene regulation have resulted from the
discovery of hundreds of miRNAs in different mamma-
lian species. Diverse expression pattern of miRNAs and
the high abundance of potential targets in the ovary have
led to the notion of their importance in the regulation of
ovarian function. A large number of miRNAs has now
been identified in the ovary [10,11] and found to be reg-
ulated by gonadotropins during follicular development
[12,13]. Recent studies indicate that miRNAs are in-
volved in the regulation of steriodogenesis, cell prolifera-
tion and apoptosis in human granulosa cells [14,15].
Differential expression of miR-23a, miR-23b,miR-542–3p,
miR-211, and miR-17–5p in granulosa/cumulus cells
from women undergoing assisted reproduction suggests
aberrant miRNA expression may be an underlying eti-
ology in female infertility [16,17]. Furthermore, miRNAs
have been implicated to play a role in obesity and meta-
bolic syndrome, including insulin resistance [18], condi-
tions often associated with PCOS. However, whether
miRNAs contribute to the follicle arrest, dysregulated
steroid production and insulin resistance in PCOS is
not known. Understanding how miRNAs are regulated
in the ovary and the identification of their specific
targets and functions may offer novel insights into the
etiology of PCOS and the development of target-specific
gene regulation for its treatment.
Hyperandrogenism is one key feature in human PCOS
patients and circulating levels of androgens, such as tes-
tosterone, androstenedione and dihydrotestosterone
(DHT), are elevated in these patients [19,20]. A number
of animal models have been developed that allow one to
focus on different aspects of PCOS pathology, including
ovarian follicular and metabolic features [21-23]. A re-
cent report on a rat PCOS model involving chronic
DHT implant mimics the hyperandrogenic status and
exhibits both polycystic ovaries and metabolic abnormal-
ities similar to those in human PCOS [23], allowing one
to examine not only ovarian characteristics but also
metabolic features of PCOS.We hypothesize that PCOS is associated with
dysregulation of ovarian miRNAs which may be involved
in post-transcriptional regulation of genes involved in the
ovarian pathology. Taking advantage of DHT-induced rat
PCOS model, we tested this hypothesis by comparing the
expression of 349 miRNAs between DHT-treated vs un-
treated rat ovaries. Moreover, selected candidate miRNAs
were investigated for their localization in follicular cells.
Results of the present study revealed that PCOS is associ-
ated with differential expression of regulatory non-coding
miRNAs in rat ovaries.
Materials and methods
DHT-filled silastic capsules preparation
The DHT-filled capsules were prepared as previously de-
scribed [24]. Silastic tubing (I.D. 1.98 mm x O.D. 3.18 mm;
Dow Corning, Cat. No. 2415577, Midland, MI), cut to an
appropriate length to achieve a desired surface area of
299.70 mm2, was filled with DHT (Sigma) from 1 ml syr-
inge. The tubing was closed at each end (3 mm) with a
sealant (Silicone Type A, Dow Corning Cat. No. 891,
Midland, MI), ensuring that adhesive is in contact with
tubing walls and that there are no air bubbles. Control
capsules were empty with only sealant on both ends. After
overnight dry, capsules were rinsed for 2 days in 3% bovine
serum albumin (BSA) in phosphate buffer saline (PBS)
with 0.1% NaN3 solution, thoroughly washed with PBS and
sterilized by dipping briefly in 70% ethanol before use.
Animal preparation
Sprague Dawley rats (Charles River, Montreal, Canada)
were maintained on 12-h light, 12-h dark cycles and
given food and water ad libitum. All procedures were
carried out in accordance with the Guidelines for the
Care and Use of Laboratory Animals, Canadian Council
on Animal Care, and were approved by University of
Ottawa and Ottawa Hospital Research Institute Animal
Care Committee.
Animal surgery, DHT capsule implantation and animal care
Thirty-six female rats at 21 days of age were randomly
divided into two groups (control vs. DHT group) and
were implanted with a DHT-filled silicone capsule
continuous-releasing (83 μg per day; empty capsule for
controls) for 12 weeks to mimic the hyperandrogenic
state in women with PCOS, whose plasma DHT levels
are approximately 1.7-fold higher than those of healthy
control [23]. Animals were weighed weekly to monitor
body weight gain and euthanized at 12 wks post-
implantation. Ovaries were collected for analyses.
Determination of estrous cycle phases of rat
The estrous cycle of rats was monitored by microscopic
analysis of vaginal smear obtained every morning for 12
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cells associated with each phase of the estrus cycle were:
epithelial cells (proestrous; P), enucleated cornified cells
(estrous; E), equal mix of leukocytes and cornified epithelial
cells (metestrous; M) and leukocytes (diestrous; D) [25].
Determination of insulin sensitivity
Insulin sensitivity test (IST) was performed after 12 h
overnight fasting at 10 wks of surgery. Human insulin
(0.2 U/100 g body weight intravenously, Novo Nordisk
Canada Inc. Mississauga, ON, Canada) was administered
to control or DHT-treated rats through tail vein and
blood samples were obtained from the tail at 0, 5, 10, 20,
40, 80, 160 min. after insulin injection. Glucose levels
were determined by glucose test strips (ACCU-CHEK,
Roche). The insulin sensitivity index KITT was calculated
from the slope of a linear portion of the regression line
of natural logarithm of glucose versus time. Raw data
were transformed by Log KITT for analysis. KITT =
(0.693/t1/2) × 100, t1/2 represents the half-life of glucose
decay after insulin injection [26].
Ovarian tissue collection and morphological evaluation
Pairs of ovaries were excised, and weighed. For morpho-
logical evaluation, whole ovaries were embedded in par-
affin block and longitudinal sections (4 μm thick) were
stained with hematoxylin and eosin. Since the consider-
able discrepancy in estimating follicle numbers exists be-
tween studies due to different section thickness and
correction factors adopted [27], the percentage of num-
ber of cystic follicles (FC) and corpus lutea (CL) over
total follicular structure (including all kinds of follicles
and CL) per ovary were determined. A FC was defined
as an collapsed anovulatory follicle exhibiting the ab-
sence of oocyte, reduced granulosa cell layer, but intact
theca layer. The maximal longitudinal ovarian sections
were investigated to count the numbers of FC and CL,
mean of the percentage of FC and CL from 3–5 sections
after sampling every fifth section were defined as the
relative values per ovary from 5 individual animals. In an
additional experiment, three rats from DHT group at
each time point were administered with 20 IU of equine
chorionic gonadotropin (eCG; Sigma; PBS as control) for
designated time (0–30 h) to test their ovarian respon-
siveness to gonadotropin in vivo.
miRNA expression profiling
Ovarian cortex tissues were snap-frozen in liquid nitrogen
and stored at −80°C until analysis. Total RNAs including
small RNAs from 3 independent DHT (DHT1-3) treated
and 3 non-treated control (CTL1-3) ovaries have been iso-
lated using miRNeasy mini kit (Qiagen, Hilden, Germany)
following manufacturer’s protocol. Immediately after isola-
tion, contaminating DNA and divalent cations from theRNA samples were removed using TURBO DNA-free™ kit
(Ambion, Foster City, CA) according to instruction of the
manufacturer. The quality and the concentration of the
RNA samples were assessed by NanoDrop 8000 spectro-
photometer (NanoDrop, Wilmington, Delaware, USA).
Subsequently, a total of 250 ng purified RNA from each
samples were reverse transcribed for qPCR analysis,
using the QuantiMir™ RT systems (System Biosciences,
Mountain View, CA).
MiRNA expression analysis was performed using
miRNA PCR array platform containing 349 well charac-
terized Rat miRNAs including 3 endogenous controls,
namely Rat U6 snRNA, RNU43 snoRNA & U1 snRNA
(System Biosciences, Mountain View, CA, Cat #
RA680A-1) according to the user manual of miRNome
microRNA Profilers QuantiMir™ (System Biosciences,
Mountain View, CA) with some modifications. Briefly,
20 μl of cDNA from each sample mixed with 1300 μl of
Maxima 2x SYBR Green, (Fermentas Gmbh, Leon-Rot,
Germany, Cat # K0222), 50 μl of universal reverse pri-
mer and 800 μl of nuclease-free water. Five microlitres
of mixed cDNA cocktail were dispersed into each well of
384 well PCR plate containing 1 μl of pre-aliquoted
miRNA specific primer. Multichannel laboratory auto-
mation workstation was used for pipetting the mix and
mixing the reaction into 384 well plates (Biomek® NXP,
Beckman Coulter, Krefeld, Germany). The assays were
performed in ABI 7900 HT real time PCR system (Ap-
plied Biosystems, Foster City, CA, USA) with thermal
cycling programme at 52°C for 2 min, 95°C for 10 min,
40 cycles of (95°C for 15 sec, 60°C for 1 min). Dissoci-
ation stage was included at the end of the programme to
assess the Tm of the PCR amplicons and to verify the
specificity of the amplification reactions. In addition,
amplification was verified for randomly selected reac-
tions through 2.5% agarose gel electrophoresis. Data
were analysed by ΔΔCt method and normalized by the
geometric mean of the three endogenous controls
through System Bioscience’s free Software developed to
analyse PCR Array data for Rat miRNome (System Bio-
sciences, Mountain View, CA), equipped with t test. A
fold regulation of ≥ 2. P ≤ 0.05 was considered as signifi-
cant in expression differences.
Localization of selected miRNAs in ovarian cryo-section
Ovaries were fixed in 4% paraformaldehyde (pH 7.3; 4°C,
overnight) followed by incubation in 0.5M Sucrose in
DEPC-treated 1X PBS (4°C, overnight). They were embed-
ded in Tissue-Tek Oct reagent (Shandon Cryomatrix,
Thermo Cat# 6769006) in a tissue path base mold, under-
went a slow freezing process (−1°C/min rate) in a freezing
container (NALGENE™ Cryo, Cat# 5100–0001). Serial ovar-
ian sections (10 μm) were cut at −23°C using rapid sect-
ioning cryostat (Leica microsystem Nussloch GmbH,
Figure 1 DHT-treated rats show higher body weight gain,
disrupted estrous cycles, insulin resistance, responsiveness to
gonadotropin and ovarian features. (A) Weight gain of DHT-
treated rats are significantly higher than CTL animals after 5 weeks
DHT implant (***, P < 0.001). (B) Estrous cycle was evaluated by
microscopic analysis of the predominant cell type in vaginal smears
obtained daily from 10–11 weeks post-implantation. Estrous cycle
patterns were shown in two representative rats from each group.
P: proestrous; E: estrous; M: metestrous; D: diestrous. 94% of
DHT-treated rats show irregular estrous cycle versus 22% in CTL rats.
(C) Insulin Sensitivity Test (IST): Animals were injected with insulin
(0.2U/100g Body weight) through tail vein and plasma glucose levels
were measured by glucose meter at the time indicated. Data was
transformed by Log KITT for analysis. KITT=0.693/t1/2x100, t1/2
represents the half-life of glucose decay after insulin injection
(†P < 0.05). (D) 20 IU eCG was injected to DHT-treated rats for
designated time (0–30 h) and ovarian weight was assessed. Reduced
ovarian weight in DHT-treated rats was reversed by eCG treatment
in vivo (*, P <0.05; ** P < 0.01). (E) Corpus luteum and cystic follicle
numbers were counted in the maximal longitudinal ovarian sections
and percentage of FC or CL over the total follicle structure per
section were presented. Data showed that PCOS rats was bearing
large number of cystic follicles accompanying with anovulation
(CL percentage in control vs DHT was 35%, 4%, *P < 0.05; cystic
follicles (FC) was 7% vs 43%, respectively, # P < 0.05).
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slides (Menzel-Glaeser, Germany) at −80°C until hybridi-
zation began. Sections were checked for quality and re-
quired cell content at a regular interval by staining with TB
in a light microscope. Post-fixation, acetylation and protein-
ase K treatment was done as described previously [28].
Two hours of pre-hybridization was performed at 52°C in
hybridization solution (50% formamide, 5x sodium chlor-
ide/sodium citrate [SSC; pH 6.0], 0.1% Tween-20, 50 μg/ml
heparin, and 500 mg/ml yeast tRNA). Ovarian sections
were incubated overnight at 52°C in a hybridization buffer
containing 3'-Digoxigenin (DIG) labeled LNA-modified
oligonucleotide probes (1pM) for miRNA, U6 RNA and
scrambled miRNA (Exiqon, Vedbaek, Denmark) in a hu-
midified chamber. Blocking, incubation with anti-DIG-AP
antibody, washing and color development with alkaline
phosphatase substrates solution [5-Bromo-4-chloro-3-
indolyl phosphate/Nitro blue tetrazolium (BCIP/NBT)]
were performed as described previously [28]. Vector® Me-
thyl Green (Vector laboratories, Burlingame, CA) was used
as nuclear counter-stain.
Statistical analyses
All data were analyzed using Prism 5.0 statistical soft-
ware (GraphPad, San Diego, CA). The results were
presented as means ± SEM as detailed in figure legends.
Differences in body weight gains, follicle cysts and cor-
pus luteum percentage were analyzed by two-way
ANOVA, ovarian weight between groups were analyzed
by one-way ANOVA and followed by Bonferroni post-
hoc test. Insulin sensitivity in PCOS and control groups
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difference was defined at P < 0.05.Results
Characterisation of PCOS rat model
Body weight increased in PCOS rats
Body weight for individual animal was weighed weekly. As
shown in Figure 1A, weight gain in DHT-treated rats was
significantly higher than control animals over the experi-
mental period (340.32 ± 20.66 vs. 256.49 ± 21.31g, N = 18,
P < 0.001), beginning at 5 weeks after implantation.Irregularity in estrous cycle in DHT-treated rat
Estrous cycle was evaluated by microscopic analysis of
the predominant cell type in vaginal smears obtained
daily from 10–11 weeks post-implantation. Estrous cycle
pattern in a representative rat from each group is shown
(Figure 1B). During 12 days of evaluation, control rat #
22 had 3 regular estrous cycles, whereas DHT-treated
rat # 30 started at metestrous and then showed prolong
diestrous phase. 94% of animals in DHT group shown
disrupted estrous cycle compared to 22% of animals in
control group (Figure 1B, P < 0.001, N = 17).DHT-treated rats showed insulin resistance
In order to examine the metabolic phenotype of rats
which received DHT, insulin sensitivity test was
performed. Rat plasma glucose levels were determined
by glucose test strips after insulin challenge. The insulin
sensitivity index KITT was calculated and a lower KITT
suggests decreased insulin sensitivity or insulin resist-
ance [26]. Our data shows reduced insulin sensitivity in
DHT-treated rats compared to control (Control rats
Log KITT = 0.34 ± 0.03 vs. DHT-treated rats 0.23 ± 0.05,
N = 17, P < 0.05) (Figure 1C). As indicated as dotted
line in Figure 1C, it took 10 minutes for the Control rat
# 12 to change the basal glucose level from 6.9 mmol/L
to 3 mmol/L, whereas it took 40 minutes for the glucose
levels of DHT-treated rat # 5 to decrease from 6.3 to 3
mmol/L. A glucose curve shift to the right was evident
in DHT-treated rats when compared to control animals.Ovary weights were lower in DHT-treated rats
Pair ovary weight in DHT-treated rats was significantly
lower than their control counterparts (0 h: 18.93 ± 4.85
mg vs. 91.90 ± 4.48 mg. P < 0.001) (Figure 1D). To test if
DHT-treated ovaries are responsive to gonadotropin, three
DHT-treated rats per group were administered with 20 IU
of eCG (PBS as control) for designated time (0–30 h) and
the ovaries were weighed in an additional experiment.
Interestingly, the reduction of ovary weight in DHT-
treated rats was markedly rescued with longer eCGtreatment, indicating that this PCOS phenotype was re-
sponsive to gonadotropin (Figure 1D).DHT-treated rats exhibited anovulation
To assess ovarian feature of PCOS rat, ovarian morph-
ology in sections from CTL or DHT-treated rats was ex-
amined by H&E staining. Percentage of cystic follicle
(FC) and corpus luteum (CL) over the total follicular
structure were estimated in the longitudinal ovarian sec-
tions, as described in Materials and Methods. Estimation
of relative value of FC and CL number, regardless of the
total follicle numbers and their stages, is sufficient to
evaluate disruption of ovarian follicular development as
seen in PCOS. In control rat, CL accounted for 35% of
total follicular structure per section, whereas those in
DHT-treated rats were 4.3% (Figure 1E, P < 0.05). In
contrast, follicle cysts in DHT-treated rats accounted for
43% of total follicle structure, which was significantly
higher than in control rat (7%) (P < 0.05). Gonadotropin
treatment reactivated follicular development in the cystic
ovaries and induced ovulation, as the presence of CL in-
creased to 43.6% in eCG-treated rats, while FC percent-
age declined to 6.3% over the total follicle structure
(Figure 1E).Differential expression of miRNAs in the rat PCOS
Among the 346 miRNAs analysed, 25 miRNAs were
found to be highly expressed in the normal ovary when
compared to the expression level of other miRNAs
(Figure 2). Most of these 25 miRNAs were also found to
be highly expressed in DHT-treated ovary, although the
extent of their expression was different compared to the
normal ovary. Thus, the highly expressed miRNAs in con-
trol or DHT-treated ovary may be designated as ovarian
miRNAs. These include rno-miR-195, rno-miR-125a-5p,
rno-let-7a, rno-miR-16, rno-miR-30b-5p, rno-let-7c, rno-
let-7b, rno-miR-125b-5p, rno-miR-221, rno-miR-222,
rno-miR-26a, rno-miR-322, rno-miR-23a, rno-miR-191,
rno-miR-30 family, rno-miR-21, rno-miR-126, rno-
miR-23b, rno-miR-145 and rno-miR-494.
Expression of 346 miRNAs in ovaries of DHT-treated
and control rats were compared and a fold change of 2 or
more and with the P values equal to or less than 0.05 were
considered statistically significant. In general, 24% miRNAs
were differentially expressed between DHT and CTR ovary.
Among the differentially expressed miRNAs, most of the
miRNAs (80%) were evidenced as over-expressed in DHT
ovary. A total of 17 and 72 miRNAs were found to be
down- and up-regulated, respectively in DHT compared to
the CTL ovary (Figure 3). A list of differentially expressed
miRNAs (Fold change ≥ 2 and their corresponding P value)
is presented in Figure 4. Beside this group, miRNAs which
were also highly abundant in DHT-treated ovaries are
Figure 2 MiRNAs predominantly expressed in normal rat ovary compared to the expression level of other miRNAs.
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rno-miR-379*, rno-let-7d, rno-miR-24, rno-miR-673, rno-
miR-26b, rno-miR-335, rno-miR-382*, rno-miR-412, rno-
miR-99a*, rno-miR-543, rno-miR-674-3p, rno-miR-409-3p.
MiRNAs found to be primarily down-regulated in
DHT-treated rats includes rno-miR-770, rno-miR-466c,
rno-miR-21, rno-miR-31, rno-miR-182, rno-miR-183,
rno-miR-96, rno-miR-132, rno-miR-182, rno-miR-384-3p
and rno-miR-184.Figure 3 Scatter plot of miRNA expression by miRNA
microarray analysis. The expression profile of 346 miRNAs as
log10 (2^-Delta Ct) in PCOS (DHT) and in control group (CTL) is
plotted. Specific miRNA expression positioned on the mid-line
indicates no differential expression. Whereas lines above or under
the mid line denotes the boundary of 2 fold regulation of miRNA
expression. Red and green circles represent the number of miRNAs
in DHT ovary significantly (P < 0.05 and 2 fold-change cut off) over-
expressed and down-regulated, respectively.In situ localization of differentially expressed miRNAs
in rat PCOS
Cell-specific expression of differentially regulated miRNAs
across different follicular stages in control and DHT-
treated rats were compared by in situ localization
(Figure 5). These included rno-miR-24, rno-miR-31,
rno-miR-96, rno-miR-183, rno-miR-222, rno-miR-489,
U6 snRNA (positive control) and scrambled miRNA
(negative control). Most of these miRNAs were local-
ized in theca and granulosa cells as well as in oocytes
at early stages of follicular development. Interestingly,
miRNAs in the ovary undergoing or became cystic
condition were differentially localized in the follicular
cells in the advanced stages (Figure 5). Most of the
miRNAs were localized in the follicular theca cells of
DHT-treated ovaries. For example, rno-miR-96, rno-
miR-31 and rno-miR-222 were exclusively expressed inFigure 4 Plot diagram of the magnitude of fold regulation of
most differentially regulated miRNAs in DHT ovary compared
to control. The degree of expression difference by 2 or more fold
regulation (log2 of Fold change of DHT/control: left Y axis) is presented
by blue circle with their corresponding P-value (red circle on the right Y
axis) of 31 screened miRNAs in DHT ovary compared to control.
Figure 5 In situ localization of miRNAs across different follicular
stages in DHT-treated ovaries. Expression of miRNAs is detected
as purplish blue color precipitate of BCIP/NBT from the hybridization
of specific miRNA probe, whereas green color indicates cellular DNA
(stained by methyl green). Scale bar indicates 100 μm and black
arrow shows detected area for the particular miRNA.
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rno-miR-183 were highly expressed in the theca and,
to a lesser extent, in the granulosa cells of the cystic
follicles (Figure 5), Rno-miR-31 and rno-miR-96 were
present in the cumulus granulosa cells. Occasionally,
expression of rno-miR-489 was most noticeable in the
theca and cumulus cells of FC. Thus, most of the dif-
ferentially expressed miRNAs in the cystic ovary were
predominantly localized in the theca cells.
Functional classification of differentially expressed miRNA
To explore and identify dysregulated molecular pathways
resulting from altered miRNAs in DHT-treated ovaries,
miRNAs highly enriched or markedly reduced in these
ovaries were subjected to Ingenuity pathway analysis (IPA;
http://www.ingenuity.com). MiRNA target genes and their
respective molecular pathways were filtered and priori-
tized. Only highly predicted and experimentally validated
targets were considered as the target genes of miRNA.
Among the fourteen miRNAs mapped to the ingenuity da-
tabases, twelve (rno-let-7d, rno-miR-132, rno-miR-182,
rno-miR-183, rno-miR-184, rno-miR-21, rno-miR-221,
rno-miR-24, rno-miR-25, rno-miR-26b, rno-miR-31 and
rno-miR-96) had 171 experimentally validated targets.
When highly predicted genes were included to the out-
come, a total of 2459 target genes were found to be
targets of 14 differentially expressed miRNAs. The mo-
lecular pathways dysregulated by these differentially
expressed miRNAs in DHT-treated ovaries was evaluatedand included signalling by androgen, aldosterone,
VEGF, FGF, growth hormone, 14-3-3, calcium, estro-
gen receptor, G-Protein coupled receptor, glucocortic-
oid receptor, and apoptosis as well as in ovarian cancer
signalling and androgen and oestrogen metabolism
(Table 1).
Discussion
PCOS is a complex and heterogeneous endocrine condi-
tion characterized by hyperandrogenemia, hyperinsu-
linemia, insulin resistance, and chronic anovulation.
Using a rodent model for PCOS which recapitulates the
reproductive and metabolic phenotypes of the human
conditions [23], we have begun to examine molecular
and cellular mechanisms underlying the dysregulated
reproductive and metabolic functions of PCOS. We
have demonstrated that chronically androgenised rats,
exhibited increased body weight, disrupted estrus cy-
clicity, decreased insulin sensitivity and decreased ova-
rian weight. In the present study we have for the first time
that these phenotypes are associated with dysregulation
of gene regulatory noncoding miRNA.
Ovarian growth is the result of a series of complex and
coordinated processes, which include morphological and
functional changes in different follicular cells and their
interactions. Among the small non-coding RNAs associ-
ated to various biological and physiological disorders
(sncRNAs), miRNAs are the best characterized. Studies
on the bovine and mouse ovary have demonstated the
presence of miRNAs and suggested their potential role
in ovarian functions [10,29]. Several intra-ovarian regula-
tors and their receptors have been predicted as targets of
this ovarian miRNAs, which mediate important intracel-
lular events necessary for normal follicular development
and functions.
Although miRNAs are expressed in the human, mouse
and cow ovaries [10,14,29-34], little is known of their
role and dysregulation in PCOS. The present study rep-
resents the first report on the dysregulation of miRNAs
in a rat ovary chronically exposed to DHT, a condition
mimicking the hyperandrogenic condition in human
PCOS. Among the miRNAs examined, 79 miRNAs
(24%) responded to the hyperandrogenic condition and
interestingly, 80% of which were upregulated compared
to the control group supporting the notion that hyper-
androgenic condition down-regulates androgen recep-
tors in the granulosa cells [35] which could be mediated
by these upregulated miRNAs (rno-miR-379*, rno-let-7d,
rno-miR-24, rno-miR-673, rno-miR-26b, rno-miR-335,
rno-miR-382*, rno-miR-412, rno-miR-99a*, rno-miR-543,
rno-miR-674-3p, rno-miR-409-3p). It has been reported
that the expression of miR-143, let-7a, miR-15b is under
negative control of follicle stimulating hormone (FSH)
during follicular development [36] and may be involved in
Table 1 Molecular pathways regulated by miRNAs in DHT-treated ovaries
Molecular pathways List of miRNA
Ovarian cancer signalling rno-miR-96↓, rno-miR-25↑, rno-miR-24↓, rno-miR-221↓, rno-miR-21↓, rno-miR-183↓,
rno-miR-182↓, rno-miR-132↓, rno-let-7d↑
Androgen signalling rno-let-7d↑, rno-miR-132↓, rno-miR-182↓, rno-miR-183↓, rno-miR-184↓, rno-miR-21↓,
rno-miR-221↓, rno-miR-24↓, rno-miR-25↓, rno-miR-26b↑, rno-miR-31↓, rno-miR-335↑, rno-miR-384-3p↓
Androgen & estrogen metabolism rno-miR-96↓, rno-let-7d↑, rno-miR-24↓, rno-miR-26b↑, rno-miR-21↓, rno-miR-26b↑, rno-miR-31↓
Aldosterone signalling (epithelial cells) rno-miR-182↓, rno-miR-183↓, rno-let-7d↑, rno-miR-132↓, rno-miR-182↓, rno-miR-21↓, rno-miR-221↓,
rno-miR-24↓, rno-miR-25↑, rno-miR-26b↑, rno-miR-335↑, rno-miR-384-3p↓, rno-miR-96↓
VEGF signalling rno-miR-96↓, rno-miR-182↓, rno-miR-31↓
RhoA signalling rno-miR-132↓, rno-miR-182v, rno-miR-183↓, rno-miR-384-3p↓, rno-miR-96↓
14-3-3-mediated Signalling rno-miR-96↓, rno-miR-384-3p↓, rno-miR-335↑, rno-miR-31↓, rno-miR-26b↑, rno-miR-25↑,
rno-miR-24↓, rno-miR-221↓, rno-miR-21↓, rno-miR-184↓, rno-miR-183↓, rno-miR-182↓,
rno-miR-132↓, rno-let-7d↑
Apoptosis signalling rno-miR-25↑, rno-let-7d↑, rno-miR-182↓, rno-miR-221↓, rno-miR-24↓, rno-miR-25↑, rno-miR-26b↑,
rno-miR-31↓, rno-miR-335↑, rno-miR-384-3p↓, rno-miR-96↓
Calcium signalling rno-miR-384-3p↓, rno-let-7d↓, rno-miR-132v, rno-miR-183↓, rno-miR-21↓, rno-miR-221↓,
rno-miR-2↓5, rno-miR-26b↑, rno-miR-384-3p↓, rno-miR-96↓
Estrogen receptor signalling rno-miR-182↓, rno-miR-96↓, rno-let-7d↑, rno-miR-132↓, rno-miR-182↓, rno-miR-24↓,
rno-miR-25↑, rno-miR-26b↑, rno-miR-335↑, rno-miR-384-3p↓
FGF Signalling rno-let-7d↑, rno-miR-132↓, rno-miR-182↓, rno-miR-183↓, rno-miR-21↓, rno-miR-221↓,
rno-miR-384-3p↓, rno-miR-96
G-Protein coupled receptor signalling rno-let-7d↑, rno-miR-182↓, rno-miR-183↓, rno-miR-21↓, rno-miR-24↓, rno-miR-25↑, rno-miR-26b↑,
rno-miR-31↓, rno-miR-335↑, rno-miR-384-3p↓, rno-miR-96↓
Focal adhesion kinase-1 (FAKn) rno-miR-25↑, rno-miR-384-3p↓, rno-miR-96↓, rno-miR-183↓, rno-miR-26b↑, rno-miR-182↓,
rno-miR-21↓, rno-miR-24↓, rno-miR-31↓
Glucocorticoid receptor Signalling rno-let-7d↑, rno-miR-182↓, rno-miR-221↓, rno-miR-24↓, rno-miR-25↑, rno-miR-26b↑
Growth hormone Signalling rno-let-7d↑, rno-miR-182↓, rno-miR-183↓, rno-miR-21↓, rno-miR-24↓, rno-miR-25↑, rno-miR-26b↑
Inositol phosphate metabolism rno-miR-335↑, rno-let-7d↑, rno-miR-132↓, rno-miR-182↓, rno-miR-221↓, rno-miR-24↓, rno-miR-25↑,
rno-miR-26b↑, rno-miR-335↑, rno-miR-384-3p↓, rno-miR-96↓
P53 signalling rno-miR-132↓, rno-miR-183↓, rno-miR-21↓, rno-miR-221↓, rno-miR-24↓, rno-miR-25↑, rno-miR-26b↑,
rno-miR-31v↓, rno-miR-96↓
(↑ denotes upregulation and ↓ denotes downregulation).
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tion [37]. Thus, it is possible that the down-regulation
of miRNAs (rno-miR-770, rno-miR-466c, rno-miR-31,
rno-miR-183, rno-miR-96, rno-miR-132, rno-miR-182,
rno-miR-384-3p and rno-miR-184) observed in this
study could be associated with promoted thecal hyper-
androgenesis [37,38]. Similarly, stepwise artificial neural
networks analysis revealed predictive miRNA signatures
(miR-342, miR-299, miR-217, miR-190, miR-135b, miR-
218) corresponding to oestrogen receptor status in
breast cancer [39]. These findings raises the possibility
that the modulated miRNA expression by exogenous
DHT treatment activates estrogen receptors (ERs) to
exert indirect steroidal actions on the follicular cells or
directly on androgen receptor pathway for the regula-
tion of androgen metabolism [40].
Recent evidences suggest that miRNAs are involved in
the regulation of steroid hormone receptors (SHRs) in
ovarian follicle growth and hormone-responsive cancers.
Follicular development is the result of tightly regulated
activities of FSH, estrogen, androgen and luteinizing hor-
mone receptor (LHR) in granulosa and theca cells, aswell as oocyte in response to hormonal stimulation and
actions of intra-ovarian regulators [15]. MicroRNAs ex-
pression profile and analysis of their target genes
revealed that microRNAs exhibits characteristics import-
ant in regulating downstream LHR signaling in ovarian
cancer cells [41]. MiR-132, 5-fold down-regulation in
DHT-treated group compared to control in this study,
has previously been shown to be related to luteinizing
hormones [12], raising the possibility that elevated LH
in PCOS could involve the expression and action of
miR-132.
Androgen Receptors (ARs) mRNA is predominantly
expressed in rat granulosa cells and its expression de-
creases with the stage of follicle development [35].
Hyperandrogenemia induced by DHT is characterized
by down-regulation of granulosa cell AR in rat preantral
which could be restored by FSH administration [35].
Ovarian follicle expression of miR-221 and miR-222 has
been reported to be repressed by androgens [42-44]
which regulates cell proliferation by targeting p27/kip1
[44,45]. Here we observed higher expression of miR-222
in the DHT-induced PCOS rats, a response most
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licles. Interestingly, its expression pattern changes with
increased follicular growth and antrum formation. In the
cystic follicle, expression of miR-222 becomes restricted
to theca only, suggesting that miR-222 modulates AR ex-
pression and hereby paracrine regulation.
Clinical studies have shown that follicular ERα and ERβ
expression is significant altered in PCOS [46]. In breast
cancer cells, over-expression of miR-221, miR-222, let-7
and miR-20b is associated with reduced of ERα protein
content, signaling and expression of ERα target genes
[47-49]. Our present study also showed higher expression
of these miRNAs in the induced PCOS, consistent with a
similar mechanism found in the breast cancer cells and
their possible role in the regulation of ERα signaling. In
situ localization shows specific expression of miR-222 in
the theca cells (Figure 5) where it may be involved in
regulation of the ERα. In addition to miR-221/222, sev-
eral studies also highlighted the differential regulation
of let-7d, let-7f, miR-25 and miR-26b in prostate and
breast cancer, as well as in leukemia by the estrogen
receptor pathways and that their expression was up-
regulated in ERα-positive cells [50-52]. Expression ana-
lysis of these miRNAs revealed their higher expression
in PCOS, raising the possibility that estrogen-mediated
regulation of these miRNAs might be involved in the
etiology of PCOS. Unlike other miRNAs in DHT-
treated PCOS rats, miR-183 was found to be highly
expressed in granulosa cells of control ovaries but was
down-regulated by 10-fold in the PCOS counterpart.
Interestingly, this miRNA was found to be correlated
with estrogen receptor in breast cancer [53].
Hyperandrogenism in PCOS is one of the main causes
for early follicle excess, which induces nuclear forkhead
box transcription factors 3a (FOXO3a) exclusion and
follicular arrest [54]. FOXO3a, a target of miR-96, pro-
motes cancer cell proliferation [55]. Accordingly, expres-
sion of miR-96 in PCOS shows a 6-fold down-regulation
compared to control ovary and is localized in the theca
and cumulus-granulosa of cystic follicles. Thus, the cell
proliferation in the preantral follicles in hyperandrogenic
condition could be induced through a mechanism utiliz-
ing miR-96-mediated regulation.
PCOS is a complex syndrome with both reproductive
and metabolic disorders. Although the rat PCOS model
(DHT-treatment) simulates the hyperandrogenic state
found in human PCOS and recapitulates some of the phe-
notypes of the human syndrome (obesity, disruption of
menstrual cycle, insulin resistance), an inherent problem
of any animal model for the complex syndrome is that it
does not address all the phenotypes in PCOS. While the
rat PCOS model may provide some mechanistic insight in
the pathophysiology of the human syndrome, the signifi-
cant findings from the animal studies need to be validatedin the human context. In addition, although miRNAs are
known to regulate multiple gene targets in different sys-
tem [56,57], they can also be regulated by other paracrine/
autocrine factors [44,58]. The precise target (s) for the
reported dysregulated miRNA and their immediate down-
stream processes need to be defined.
In summary, using an androgenized rat model which
recapitulates many of the reproductive and metabolic
phenotypes of human PCOS, we have shown that
miRNAs are differentially regulated in a follicular cell-
specific manner. Since one given miRNA could target
multiple mRNAs of different genes and a given target
may be regulated by multiple miRNAs [59], whether
these miRNAs involve in the dysregulation of the hor-
mone receptors (AR, FSHR and ER) and intra-ovarian
regulators of ovarian follicle growth and function in
PCOS is unknown. The expression of predicted target
genes and their regulation by these miRNAs needs to be
clarified by further experiments. Our ongoing studies
not only include target gene expression analysis but also
their correlation with the miRNAs, and functional ana-
lysis. Taken together, the present findings support the
notion that the present DHT-treated rat model is useful
for investigating the role and regulation of miRNAs in
the molecular and cellular mechanism of PCOS and may
offer new insights for the treatment of reproductive and
metabolic disorders associated to PCOS.
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